Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $30.55.

A number of analysts have weighed in on the stock. Citigroup boosted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Guggenheim boosted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 target price on the stock.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $29.50 on Friday. The firm’s fifty day moving average price is $28.41 and its two-hundred day moving average price is $24.64. The stock has a market cap of $21.11 billion, a PE ratio of -25.21 and a beta of 1.14. Roivant Sciences has a fifty-two week low of $10.58 and a fifty-two week high of $30.33.

Insider Activity at Roivant Sciences

In other news, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the transaction, the chief executive officer owned 1,647,546 shares in the company, valued at approximately $48,750,886.14. This trade represents a 10.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,745,173 shares of company stock valued at $103,639,917 in the last quarter. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of ROIV. Jones Financial Companies Lllp lifted its holdings in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares during the period. SBI Securities Co. Ltd. lifted its holdings in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP lifted its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Finally, Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the fourth quarter valued at $47,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.